How can natural products serve as a viable source of lead compounds for the development of new/novel anti-malarials?

Malaria Journal

Volumn 10, Issue SUPPL. 1, 2011, Pages

  Guantai, Eric ^a   Chibale, Kelly ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; FEBRIFUGINE; HALOFUGINONE; ISOFEBRIFUGINE; NATURAL PRODUCT; SALINOSPORAMIDE A; SPIROINDOLONE; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; DRUG METABOLISM; HUMAN; MALARIA; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTIMALARIALS; BIOLOGICAL PRODUCTS; DATABASES, CHEMICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MOLECULAR STRUCTURE; PLANTS; PLASMODIUM;

EID: 79952765894     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-S1-S2     Document Type: Review

References (56)

1. World Malaria Report 2008. World Health Organization
2. Guidelines for the treatment of malaria. World Health Organization, 2006
3. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. RN Price F Nosten, Drug Resist Update 2001 4 187 196 10.1054/drup.2001.0195 (Pubitemid 33089456)
4. WHO Technical Report Series 2000. World Health Organization Expert Committee on Malaria
5. Antimalarial drug resistance and combination chemotherapy. N White, Phil Trans R Soc Lond B biol Sci 1999 354 739 749 10.1098/rstb.1999.0426 (Pubitemid 29365622)
6. Artemisinin-based combination therapies (ACTs): best hope for malaria but inaccessible to the needy. TK Mutabingwa, Acta Trop 2005 95 305 315 10.1016/j.actatropica.2005.06.009 16098946 (Pubitemid 41207297)
7. Resisting resistance: dealing with the irrepressible problem of malaria. G Edwards GA Biagini, BriJ Clin Pharmacol 2006 61 690 693 10.1111/j.1365-2125. 2006.02674.x (Pubitemid 43794795)
8. Plant-derived natural product research aimed at new drug discovery. H Itokawa SL Morris-Natschke T Akiyama K-H Lee, J Nat Med 2008 62 263 280 10.1007/s11418-008-0246-z 18425692
9. Antimalarial agents from plant sources. S Saxena N Pant DC Jain RS Bhakuni, Curr Sci 2003 85 1314 1329 (Pubitemid 39204545)
10. Biological screening of natural products and drug innovation in China. M-W Wang X Hao K Chen, Phil Trans R Soc B 2007 362 1093 1105 10.1098/rstb.2007.2036 17317643 (Pubitemid 47056805)
11. Quinghaosu (artemisinin): An antimalarial drug from China. DL Klayman, Science 1985 228 1049 1055 10.1126/science.3887571 3887571 (Pubitemid 15227365)
12. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. RK Haynes, Curr Top Med Chem 2006 6 509 537 10.2174/ 156802606776743129 16719805
13. Antimalarials from nature. K Kaur M Jain T Kaur R Jain, Bioorg Med Chem 2009 17 3229 3256 10.1016/j.bmc.2009.02.050 19299148
14. Antimalarial natural products of marine and freshwater origin. K Gademann J Kobylinska, Chem Rec 2009 9 187 198 10.1002/tcr.200900001 19424997
15. Plant-derived antimalarial agents: new leads and efficient phytomedicines. Part II. Non-alkaloidal natural products. R Batista AJ Silva Jnr AB Oliviera, Molecules 2009 14 3037 3072 10.3390/molecules14083037 19701144
16. Drug discovery and natural products: end of an era or an endless frontier? JW-H Li JC Vederas, Science 2009 325 161 165 10.1126/science.1168243 19589993
17. Culturability and secondary metabolite diversity of extreme microbes: expanding contribution of deep sea and deep-sea vent microbes to natural product discovery. RK Pettit, Mar Biotechnol 2010 Online publication:DOI 10.1007/s10126-010-9294-y 20437069
18. Strategies for discovering drugs from previously unexplored natural products. A Harvey, Drug Disc Today 2000 5 294 300 10.1016/S1359-6446(00)01511-7 (Pubitemid 30386930)
19. Natural products as lead-structures: a role for biotechnology (Editorial). JE John, Drug Discov Today 2010 15 409 410 10.1016/j.drudis.2010. 02.008 20206288
20. Production of artemisinin by genetically-modified microbes. Q Zeng F Qui L Yuan, Biotechnol Lett 2008 30 581 592 10.1007/s10529-007-9596-y 18008167
21. Marine Actinomycetes: a new source of compounds against the human malaria parasite. J Prudhomme E McDaniel N Ponts S Bertani W Fenical P Jensen K le Roch, PLoS ONE 2008 3 2335 10.1371/journal.pone.0002335 18523554
22. Combination effects of chloroquine with the febrifugine and isofebrifugine mixture against a blood-induced infection with chloroquine-resistant Plasmodium berghei NK65 in ICR Mice. A Ishih T Suzuki M Watanabe T Miyase M Terada, Phytother Res 2003 17 1234 1236 10.1002/ptr.1365 14669265 (Pubitemid 38057188)
23. Hybrid drugs for malaria. JJ Walsh A Bell, Curr Pharm Des 2009 15 2970 2985 10.2174/138161209789058183 19754373
24. Preparation and antimalarial activities of "Trioxaquines", new modular molecules with a trioxaneskeleton linked to a 4-aminoquinoline. D Dechy-Cabaret F Benoit-Vical A Robert B Meunier, Chembiobhem 2000 1 281 283 10.1002/1439-7633(20001117)1:4<281::AID-CBIC281>3.0.CO;2-W
25. Drug-like properties: concepts, structure, design and methods: from ADME to toxicity optimization. EK Kerns L Di, Academic Press/Elselvier 2008
26. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4 and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. D Projean B Baune R Farinotti JP Flinois P Beaune AM Taburet A Ducharme, Drug Metab Dispos 2003 31 748 754 10.1124/dmd.31.6.748 12756207 (Pubitemid 36617663)
27. In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum. S Fu A Björkman B Wåhlin D Ofori-Adjei O Ericsson F Sjöqvist, Br J Clin Pharmacol 1986 22 93 96 3527245 (Pubitemid 17177210)
28. Metabolites of febrifugine and its synthetic analogue by mouse liver S9 and their antimalarial activity against Plasmodium malaria parasite. S Hirai H Kikuchi H-S Kim K Begum Y Wataya H Tasaka Y Miyazawa K Yamamoto Y Oshima, J Med Chem 2003 46 4351 4359 10.1021/jm0302086 13678413 (Pubitemid 37153015)
29. Alkaloids of Dichroa febrifuga Lour. FA Kuehl CF Spencer K Folkers, J Am Chem Soc 1948 70 2091 2093 10.1021/ja01186a031 18863804
30. Synthesis and evaluation of febrifugine analogues as potential antimalarial agents. S Zhu L Meng Q Zhang L Wei, Bioorg Med Chem Lett 2006 16 1854 1858 10.1016/j.bmcl.2006.01.009 16434194 (Pubitemid 43273263)
31. Synthesis and biological evaluation of febrifugine analogues as potential antimalarial agents. S Zhu Q Zhang C Gudise L Wei E Smith Y Zeng, Bioorg Med Chem 2009 17 4496 4502 10.1016/j.bmc.2009.05.011 19467876
32. Molecular modeling evaluation of the antimalarial activity of artemisinin analogues: molecular docking and rescoring using Prime/MM-GBSA Approach. M Srivastava H Singh PK Naik, Curr Res J Biol Sci 2010 2 83 102
33. Antimalarial activities and therapeutic properties of febrifugine analogs. S Jiang Q Zeng M Gettayacamin A Tungtaeng S Wannaying A Lim P Hansukjariya CO Okunji S Zhu D Fang, Antimicrob Agents Chemother 2005 49 1169 1176 10.1128/AAC.49.3.1169-1176.2005 15728920 (Pubitemid 40327741)
34. Dictionary of natural products. 2010
35. A marine natural product database. J Lei J Zhou, J Chem Inf Comput Sci 2002 42 742 748 12086536 (Pubitemid 35355282)
36. Spirotetrahydro b-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria. BKS Yeung B Zou M Rottmann SB Lakshminarayana SH Ang SY Leong J Tan J Wong S Keller-Maerki C Fischli A Goh EK Schmitt P Krastel E Francotte K Kuhen D Plouffe K Henson T Wagner EA Winzeler F Petersen R Brun V Dartois TT Diagana TH Keller, J Med Chem 2010 53 5155 5164 10.1021/jm100410f 20568778
37. Spiroindolones, a potent compound class for the treatment of malaria. M Rottmann C McNamara BKS Yeung MCS Lee B Zou B Russell P Seitz DM Plouffe NV Dharia J Tan SB Cohen KR Spencer GE Gonzlez-Pez SB Lakshminarayana A Goh R Suwanarusk T Jegla EK Schmitt HP Beck R Brun F Nosten L Renia V Dartois TH Keller DA Fidock EA Winzeler TT Diagana, Science 2010 329 1175 1180 10.1126/science.1193225 20813948
38. Preparation of a natural product extract library for investigation against disease states specific to defence health: a mini long range research project. SPB Ovenden M Chavchich M Cobbe EJ Pigott MJ Laws MD Edstein, Defence Science and Technology Organisation, Department of Defence, Australian Government 2009 DSTO-TR-2255
39. Metabolite profiling of the intraerythrocytic malaria parasite Plasmodium falciparum by 1H NMR spectroscopy. R Teng PR Junankar WA Bubb C Rae P Mercier K Kirk, NMR Biomed 2009 22 292 302 10.1002/nbm.1323 19021153
40. Glycerol: An unexpected major metabolite of energy metabolism by the human malaria parasite. L-Y Lian M Al-Helal AM Roslaini N Fisher PG Bray SA Ward GA Biagini, Malar J 2009 8 doi:10.1186/1475-2875-8-38 10.1186/1475-2875-8-38 19267910
41. Identification and characterization of molecular targets of natural products by mass spectrometry. K-W Cheng C-C Wong M Wang Q-Y He F Chen, Mass Spectrom Rev 2010 29 126 155 19319922
42. The evolution of metabolic profiling in parasitology. E Holmes, Parasitology 2010 137 1437 1449 10.1017/S0031182010000260 20441681
43. Natural products: chemical instruments to apprehend biological symphony. M Pucheault, Org Biomol Chem 2008 6 424 432 10.1039/b713022h 18219406 (Pubitemid 351161727)
44. Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. GG Harrigan DJ Brackett LG Boros, Mini-Rev Med Chem 2005 5 13 20 15638788 (Pubitemid 40124839)
45. Effect of fosmidomycin on metabolic and transcript profiles of the methylerythritol phosphate pathway in Plasmodium falciparum. MB Cassera EF Merino VJ Peres EA Kimura G Wunderlich AM Katzin, Mem Inst Oswaldo Cruz 2007 102 377 10.1590/S0074-02762007000300019 17568945
46. Natural products in drug discovery. AL Harvey, Drug Disc Today 2008 13 894 901 10.1016/j.drudis.2008.07.004
47. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. BF Cravatt AT Wright JW Kozarich, Annu Rev Biochem 2008 77 383 414 10.1146/annurev.biochem.75.101304.124125 18366325
48. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. AJ Barrett AA Kembhavi MA Brown H Kirschke CG Knight M Tamai K Hanada, Biochem J 1982 201 189 198 7044372 (Pubitemid 12038477)
49. Cysteine proteases of malaria parasites. PJ Rosenthal, Int J Epidemiol 2004 34 1489 1499
50. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. D Greenbaum KF Medzihradszky A Burlingame M Bogyo, Chem Biol 2000 7 569 581 10.1016/S1074-5521(00)00014-4 11048948
51. Natural products and their biological targets: proteomic and metabolomic labeling strategies. T Böttcher M Pitscheider SA Sieber, Angew Chem Int Ed Engl 2010 49 2680 2698 20333627
52. Classical vs reverse pharmacology in drug discovery. T Takenaka, BJU Int 2001 88 Suppl 2 7 10 11589663 (Pubitemid 32955444)
53. Genome sequence of the human malaria parasite Plasmodium falciparum. MJ Gardner N Hall E Fung O White M Berriman RW Hyman JM Carlton A Pain KE Nelson S Bowman, et al. Nature 2002 419 498 511 10.1038/nature01097 12368864
54. PlasmoDB: An integrative database of the Plasmodium falciparum genome. Tools for accessing and analyzing finished and unfinished sequence data. The Plasmodium Genome Database Collaborative, Nucleic Acids Res 2001 29 66 69 10.1093/nar/29.1.66 11125051
55. Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. RA Bauer JM Wurst DS Tan, Curr Opin Chem Biol 2010 14 308 314 10.1016/j.cbpa.2010.02.001 20202892
56. Quantifying Biogenic Bias in Screening Libraries. J Hert JJ Irwin C Laggner MJ Keiser BK Shoichet, Nat Chem Biol 2009 5 479 483 10.1038/nchembio.180 19483698